Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
clinical-stage biotech company developing first-in-class drugs for hepatitis B, cancer, autoimmune diseases, and rare genetic disorders.
Drug Farm is a clinical-stage biopharmaceutical company based in Shanghai, China, that develops treatments targeting innate immunity using forward genetics technology and artificial intelligence. The enterprise focuses on creating first-in-class therapeutics for hepatitis B, oncology, autoimmune diseases, and rare genetic disorders. To support its clinical pipeline, the business has raised a total of $83 million in venture capital funding, which includes a $56 million financing round in 2021 and a subsequent $27 million Series C round. Under the leadership of Chief Executive Officer Henri Lichenstein, the organization advanced its lead hepatitis B drug candidate into clinical trials. Furthermore, the company established a cooperative agreement with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases to develop treatments for retinal conditions. Drug Farm was founded in 2015 by Tian Xu and Cong Xu.
Drug Farm has raised $83.0M across 2 funding rounds.
Drug Farm has raised $83.0M in total across 2 funding rounds.
Drug Farm has raised $83.0M across 2 funding rounds. Most recently, it raised $27.0M Series C in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 16, 2023 | $27M Series C | YD Capital | Betta Capital, Haoyue Capital, Jiashan County State Owned Assets Investment, Wedo Venture Management | Announced |
| Feb 9, 2021 | $56M Venture Round | — | BVCF Management, WuXi AppTec, Zuig | Announced |
Drug Farm has raised $83.0M in total across 2 funding rounds.
Drug Farm's investors include YD Capital, Betta Capital, Haoyue Capital, Jiashan County State-owned Assets Investment, Wedo Venture Management, BVCF Management, WuXi AppTec, ZUIG.